One Capital Management LLC Buys 5,541 Shares of Guardant Health, Inc. $GH

One Capital Management LLC boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 17.5% during the fourth quarter, Holdings Channel reports. The firm owned 37,181 shares of the company’s stock after purchasing an additional 5,541 shares during the quarter. One Capital Management LLC’s holdings in Guardant Health were worth $3,798,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in GH. AQR Capital Management LLC raised its position in Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after acquiring an additional 25,831 shares during the period. Empowered Funds LLC purchased a new stake in shares of Guardant Health in the first quarter worth $274,000. Sei Investments Co. grew its stake in Guardant Health by 15.8% during the second quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock valued at $4,023,000 after acquiring an additional 10,538 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Guardant Health by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock valued at $32,922,000 after acquiring an additional 54,284 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Guardant Health by 56.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after acquiring an additional 40,209 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on GH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research note on Thursday, May 21st. Robert W. Baird began coverage on shares of Guardant Health in a report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 target price for the company. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Citigroup raised their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Twenty investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and a consensus target price of $136.37.

Insider Activity

In related news, insider Chris Freeman sold 24,406 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the transaction, the insider owned 60,034 shares in the company, valued at $7,124,234.78. The trade was a 28.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ian T. Clark sold 6,876 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $106.90, for a total transaction of $735,044.40. Following the transaction, the director owned 2,975 shares of the company’s stock, valued at approximately $318,027.50. This trade represents a 69.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 332,244 shares of company stock worth $36,156,026 over the last 90 days. 5.60% of the stock is currently owned by insiders.

Guardant Health Stock Performance

NASDAQ:GH opened at $130.17 on Wednesday. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $133.97. The firm has a market cap of $17.26 billion, a P/E ratio of -38.40 and a beta of 1.61. The firm has a 50-day simple moving average of $95.88 and a 200-day simple moving average of $100.18.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.